MARKET

ENZ

ENZ

Enzo Biochem
NYSE

Real-time Quotes | Nasdaq Last Sale

3.040
+0.050
+1.67%
After Hours: 2.900 -0.14 -4.61% 19:34 01/15 EST
OPEN
2.960
PREV CLOSE
2.990
HIGH
3.130
LOW
2.800
VOLUME
598.51K
TURNOVER
--
52 WEEK HIGH
4.850
52 WEEK LOW
1.560
MARKET CAP
145.60M
P/E (TTM)
-7.0468
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Board Directors Stopping the Steal? Enzo Biochem Flouts Shareholder Democracy
By John Jannarone It didn’t work in Washington, but some companies continue to believe that ignoring the outcome of a vote might be acceptable on Wall Street. The latest unfortunate example is Enzo Biochem, Inc., a company founded in the 1970s that has frustrated investors with a poor operational and share-price performance over the last […]
CorpGov.com · 2d ago
Biomarkers Market by Scope, Demand, Growth, Recent Developments, Emerging Trends and Forecast till 2027
Jan 11, 2021 (Heraldkeepers) -- Market's Viewpoint The Global Biomarkers Market 2020 shares are rising as the COVID 19 pandemic destabilizes other markets...
Heraldkeepers · 6d ago
Caspase Activity Assay Kit Market Overview - 2021, Key Segments, Latest Trends, Product Specification, Key Regions, Revenues, Growth Factors |Impact of COVID-19 on Global Industry
Jan 11, 2021 (The Expresswire) -- The Global “Caspase Activity Assay Kit Market” 2021 report offers the scope of different key segments and applications that...
The Express Wire · 6d ago
Roumell Asset Management Reports From Annual Meeting Of Enzo Biochem Dr. Rabbani Received ~44% Of Shares Voting For His Re-Election
Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc. CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which
Benzinga · 01/05 18:34
Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc.
, /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today announced the preliminary results at the Company's annual meeting of shareholders held on (the "Annual Meeting") based on the tally by Roumell's proxy solicitor.
PR Newswire - PRF · 01/05 18:27
ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT
Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or "The Company"), a leading biosciences and diagnostics company, today announced that it will participate in the 10 Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021 in concurrence with J.P. Morgan's 39 Annual Healthcare Conference.
GlobeNewswire · 01/05 13:00
Harbert Discovery Fund Issues Letter to the Independent Directors of Enzo Biochem, Inc.
EQNX::TICKER_START EQNX::TICKER_END
GlobeNewswire · 01/04 18:25
Enzo Biochem nabs expanded EUA nod for testing of COVID samples
Enzo Biochem (ENZ) gains 11% in premarket after receiving an expansion on its emergency use authorization ((EUA)) from the FDA to test pooled samples with up to five individual swab specimens, utilizing
Seekingalpha · 01/04 13:27
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENZ. Analyze the recent business situations of Enzo Biochem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENZ stock price target is 5.50 with a high estimate of 5.50 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 129
Institutional Holdings: 30.93M
% Owned: 64.59%
Shares Outstanding: 47.90M
TypeInstitutionsShares
Increased
23
2.59M
New
21
-1.18M
Decreased
27
1.06M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.68%
Healthcare Providers & Services
+0.36%
Key Executives
President/Treasurer
Barry Weiner
Chief Executive Officer/Chairman/Director/Secretary
Elazar Rabbani
Chief Financial Officer
David Bench
Other
Kara Cannon
Other
Dieter Schapfel
Lead Director/Independent Director
Dov Perlysky
Independent Director
Rebecca Fischer
Independent Director
Mary Tagliaferri
Independent Director
Ian Walters
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ENZ
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Enzo Biochem, Inc. stock information, including NYSE:ENZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENZ stock methods without spending real money on the virtual paper trading platform.